Stay updated on KarXT Long-Term Safety in Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the KarXT Long-Term Safety in Schizophrenia Clinical Trial page.

Latest updates to the KarXT Long-Term Safety in Schizophrenia Clinical Trial page
- Check6 days agoChange DetectedSponsor information was updated to include Karuna Therapeutics, Inc., a Bristol Myers Squibb company, and schizophrenia- and MedlinePlus Genetics-related topics were added. The standalone term Karuna Therapeutics was removed.SummaryDifference0.3%

- Check13 days agoChange DetectedRevision metadata updated: added v3.5.0. Removed v3.4.3.SummaryDifference0.0%

- Check20 days agoChange DetectedRemoved the related topics 'Schizophrenia' and 'MedlinePlus Genetics' from the page. This reduces contextual tagging and external links but does not alter the study's core information or eligibility details.SummaryDifference0.1%

- Check27 days agoChange DetectedThe page revision was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check49 days agoChange DetectedMinor updates to related topics and site revision labeling were added, with no changes to core study content, eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check56 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1 on the page.SummaryDifference0.0%

Stay in the know with updates to KarXT Long-Term Safety in Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT Long-Term Safety in Schizophrenia Clinical Trial page.